vivoVerse at the Society of Toxicology Annual Meeting in Nashville

The 2023 Society of Toxicology (SOT) Annual Meeting is coming up this month, and we will be attending! The SOT Annual Meeting is one of the largest gatherings of toxicologists from around the world. We are excited to join the thousands of attendees and hundreds of exhibitors in exchanging knowledge, publishing research findings, and learning Read more about vivoVerse at the Society of Toxicology Annual Meeting in Nashville[…]

vivoVerse moves into new HQ

vivoVerse (formerly operating as Newormics) has expanded its base of operations into a customized, newly refurbished space in Austin, Texas. The new headquarters comprises over 2400 square-foot of laboratory, office, and meeting space and is situated in the Balcones Office Park, just north of downtown and UT Austin. Here, we lead you on a quick Read more about vivoVerse moves into new HQ[…]

Newormics resumes operations

Dear Colleagues, Customers, and Collaborators: At our Newormics location in Austin, TX, we have been allowed to re-open. We have resumed operations in our lab and in our manufacturing facility as of August 1st. This means we can now be contacted for purchasing our vivoCube system, accessory kits, and for obtaining more vivoChips for your Read more about Newormics resumes operations[…]

vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office

Patent covers the vivoChip® invention that vivoVerse licensed for use in immobilization of C. elegans for high resolution imaging. AUSTIN, TX. August 5, 2020 – vivoVerse (formerly operating as Newormics), a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering Read more about vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office[…]

vivoVerse awarded SBIR Phase II grant from the NIMH

vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies. vivoVerse’s core focus is to facilitate the use of C. elegans as Read more about vivoVerse awarded SBIR Phase II grant from the NIMH[…]

Newormics launches new vivoChips for early stage worms

Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and image successfully, due to their tiny size and difficulties with using conventional anesthetics and time-consuming mounting methods. To help researchers solve these problems, Newormics is launching two new devices in our vivoChip®-2x range: vivoChip®-2x L1-L2, Read more about Newormics launches new vivoChips for early stage worms[…]

DDNews features Newormics in their latest issue in a special report on drug screening

The research of Newormics is featured in a special report in the July 2019 issue of DDNews in an article titled “Phenotypic finery: Microscopy meets the molecular in the search for phenotypic impacts in drug screening”. This article reviews cutting-edge research in drug discovery using novel microscopy and image analysis technologies to screen potential drug Read more about DDNews features Newormics in their latest issue in a special report on drug screening[…]

Newormics at the 2019 UK C. elegans meeting

Newormics is exhibiting at the 2019 UK C. elegans meeting at Imperial College London on September 16th. Come meet us and view our latest imaging solutions there. We will also have a special laboratory demo day, kindly hosted by Dr. Michalis Barkoulas at Imperial College London on September 17th. The demo will allow attendees to Read more about Newormics at the 2019 UK C. elegans meeting[…]

Newormics awarded an SBIR Phase I grant from the NIEHS

Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project “A Large-Scale Microfluidics Imaging Platform for High-Throughput Toxicity Testing using Canine Intestinal Organoids”. Currently, toxicology studies require a large number of animal testing to identify better and safer drug candidates. In an attempt to reduce Read more about Newormics awarded an SBIR Phase I grant from the NIEHS[…]